Pfenex (San Diego, CA) a commercial-stage biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars, closed a $24M Series A financing. Participants include Signet Healthcare Partners.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Circassia (United Kingdom) a clinical-stage specialty biopharmaceutical focused on therapeutic T-cell vaccines for allergies and organ transplant rejection, closed a $25M Series C financing. Participants include Imperial Innovations, Invesco Perpetual and Lansdowne Partners.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Savara Pharmaceuticals (Austin, TX) a development-stage Dry powder and nebulizer-based drug delivery solution, closed a $1.4M Series A financing. Participants were not identified.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

PTC Therapeutics (South Plainfield, NJ) a clinical-stage small molecule company focused on CF, hemophilia and muscular dystrophy, closed a $50M Series E financing. Participants include The Column Group, Delphi Ventures, CSFB Private Equity, HBM BioVentures and Novo Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutics, closed a $20M Series B financing, bringing the total round to $71M. Participants have included Chicago Growth Partners, Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas McNerney & Partners, Oxford Finance and Abingworth Management.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Therasis (New York, NY) a development-stage computational systems biology cancer HTS drug discovery platform, closed a $12M Series A financing. Participants include Tilocor Life Science.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Apnex Medical (St. Paul, MN) a clinical-stage medical device company developing an implantable treatment for moderate-to-severe obstructive sleep apnea, closed a $14M Series B financing. Participants include Domain Associates, New Enterprise Associates and Polaris Venture Partners.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Evolva (Switzerland) a clinical-stage synthetic biology small molecule company focused on proteinuri kidney and cardiovascular disease, closed a $15.2M Series B financing bringing the total round up to $42.3M. Participants include Wellington Partners, Aravis Venture Associates, Auriga Partners and Vinci Capital.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

On-Q-lty (Waltham, MA) a development stage molecular diagnostics company incorporating microfluidics and biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors, closed a $5M Series A financing, bringing the total round to $26M. Participants include Atlas Venture, Mohr Davidow Ventures, Bessemer Venture Partners, Physic Ventures and Northgate Capital.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Epizyme (Cambridge, MA) a development-stage biopharma company focused on histone methyltransferases inhibitors in oncology indications, closed a $8M Series B financings, bringing the total round to $40M. Participants include New Enterprise Associates, Bay City Capital, Amgen Ventures, Astellas Venture Partners, MPM Capital and Kleiner Perkins Caufield and Byers.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb